|
|
|
| Expression levels of serum bone morphogenetic protein-6 and TAZ of pregnant women with placenta previa and their relationship with pregnancy outcomes of the patients |
| 1. Puyang Maternity and Child Care Centers, Henan Province, 457000；2. Puyang Zhongyuan Oilfield General Hospital, Henan Province |
|
|
|
|
Abstract To investigate the expression levels of serum bone morphogenetic protein-6 (BMP6) and TAZ of pregnant women with placenta previa, and to study the correlation between of the levels of serum BMP6 and TAZ of the women and their pregnancy outcomes. Methods: From March 2019 to March 2021, 82 pregnant women with placenta previa were selected in study group. According to the situation of placenta accreta, these women were divided into in group A (42 cases with placenta accreta), group B (26 cases with placenta implantation), and group C (14 cases with placenta percreta). While 69 healthy pregnant women were included in control group during the same period. The expression levels of mRNA and protein of serum BMP6 and TAZ of the women in these group were determined by RT-PCR and Elisa methods, and the pregnancy outcomes of the women in these group were recorded. Spearman rank correlation analysis was used to explore the correlation between the expression levels of serum BMP6 and TAZ of the women and their condition of placenta previa. Pearson's product-difference correlation analysis was used to explore the correlation between the expression levels of serum BMP6 and TAZ of the women and their pregnancy outcomes. Results: The expression levels of mRNA and protein of serum BMP6 and TAZ of the women in the study group were significantly lower than those of the women in the control group. With the increase of the severity of placenta previa, the expression levels of of mRNA and protein of serum BMP6 and TAZ of the women in the study group had decreased gradually (P＜0.05). The expression levels of mRNA and protein of serum BMP6 and TAZ of the women were negatively correlated with the severity of their placenta previa (P＜0.05). The placenta weight of the women, and the neonatal birth weight and 1min Apgar score in the study groups were all significantly lower than those in the control group. With the increase of the severity of placenta previa of the women in the study group, their placenta weight, and their neonatal birth weight and 1min Apgar score had decreased gradually (P＜0.05), and the levels of mRNA and protein of their serum BMP6 and TAZ of the women in the study group were positively correlated with their placental weight, neonatal birth weight and 1-min Apgar score (P＜0.05). Conclusion: The mRNA and protein expression levels of serum BMP6 and TAZ of the pregnant women with placenta previa are decreased, and which are negatively correlated with the severity of placenta previa of these women, while were positively correlated with their pregnancy outcomes. The expression levels of serum BMP6 and TAZ of the pregnant women are expected to be the sensitive biomarkers for evaluating the severity of placenta previa of these women.
|
|
|
|
|
|
|
|
|
